Table 1

Novel chemotherapeutic regimens for NK/T-cell lymphomas

RegimenProtocolReference
AspaMetDex Escherichia colil-asparaginase: 6000 U/m2 IM, days 2, 4, 6, and 8 16 
Methotrexate: 3000 mg/m2 IV, day 1 
Dexamethasone: 40 mg orally, days 1-4 
2/3DeVIC Dexamethasone: 40 mg IV, days 1-3 56 
Etoposide: 67 mg/m2 IV, days 1-3 
Ifosfamide: 1000 mg/m2 IV, days 1-3 
Carboplatin: 200 mg/m2 IV, day 1 
VIPD Etoposide: 100 mg/m2 IV, days 1-3 57 
Ifosfamide: 1200 mg/m2 IV, days 1-3 
Cisplatin: 33 mg/m2 IV, days 1-3 
Dexamethasone: 40 mg IV or orally, days 1-4 
LVP l-asparaginase: 6000 IU/m2 IV, days 1-5 59 
Vincristine: 1.4/m2 IV, day 1 
Prednisolone: 100 mg orally, days 1-5 
GELOX Gemcitabine: 1000 mg/m2 IV, days 1 and 8 60 
E. colil-asparaginase: 6000 units/m2 IM, days 1-7 
Oxaliplatin: 130 mg/m2 IV, day 1 
SMILE Dexamethasone: 40 mg IV or orally, days 2-4 62 
Methotrexate: 2000 mg/m2 IV, day 1 
Ifosfamide: 1500 mg/m2 IV, days 2-4 
E. colil-asparaginase: 6000 U/m2 IV, days 8, 10, 12, 14, 16, 18, and 20 
Etoposide: 100 mg/m2 IV, days 2-4 
RegimenProtocolReference
AspaMetDex Escherichia colil-asparaginase: 6000 U/m2 IM, days 2, 4, 6, and 8 16 
Methotrexate: 3000 mg/m2 IV, day 1 
Dexamethasone: 40 mg orally, days 1-4 
2/3DeVIC Dexamethasone: 40 mg IV, days 1-3 56 
Etoposide: 67 mg/m2 IV, days 1-3 
Ifosfamide: 1000 mg/m2 IV, days 1-3 
Carboplatin: 200 mg/m2 IV, day 1 
VIPD Etoposide: 100 mg/m2 IV, days 1-3 57 
Ifosfamide: 1200 mg/m2 IV, days 1-3 
Cisplatin: 33 mg/m2 IV, days 1-3 
Dexamethasone: 40 mg IV or orally, days 1-4 
LVP l-asparaginase: 6000 IU/m2 IV, days 1-5 59 
Vincristine: 1.4/m2 IV, day 1 
Prednisolone: 100 mg orally, days 1-5 
GELOX Gemcitabine: 1000 mg/m2 IV, days 1 and 8 60 
E. colil-asparaginase: 6000 units/m2 IM, days 1-7 
Oxaliplatin: 130 mg/m2 IV, day 1 
SMILE Dexamethasone: 40 mg IV or orally, days 2-4 62 
Methotrexate: 2000 mg/m2 IV, day 1 
Ifosfamide: 1500 mg/m2 IV, days 2-4 
E. colil-asparaginase: 6000 U/m2 IV, days 8, 10, 12, 14, 16, 18, and 20 
Etoposide: 100 mg/m2 IV, days 2-4 

IM, intramuscularly.

Close Modal

or Create an Account

Close Modal
Close Modal